Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2008 Dec;6(6):797-803. doi: 10.1586/14787210.6.6.797.

Tipranavir: a new protease inhibitor for the pediatric population.

Author information

1
University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, CT, USA.

Abstract

Highly active antiretroviral therapy can provide sustained viral suppression and a beneficial immunological response in both antiretroviral-naive and -experienced pediatric patients infected with HIV. While there have been many antiretroviral studies in adults infected with HIV, considerably less information is available in similar HIV-infected pediatric or adolescent patients. Tipranavir, a new-generation protease inhibitor approved for use in adults with resistant HIV strains, has recently been studied in HIV-infected children and adolescents. In this article, we summarize available pharmacokinetic, safety, tolerability and efficacy data obtained from children and adolescents treated with a pediatric tipranavir formulation.

PMID:
19053893
DOI:
10.1586/14787210.6.6.797
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center